Announcing its financial results for 2023, diversified German drugmaker said it would delay a plan to break up the group for at least a couple of years. 5 March 2024
In another legal blow for opponents of the Inflation Reduction Act (IRA), a federal judge has now rejected a bid from AstraZeneca to prevent price negotiations 4 March 2024
India's pharma landscape has undergone a significant shift towards collaboration and partnership between global big pharma and domestic firms in recent years to 21 February 2024
The Yellow Card Biobank, a pilot launched by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and Genomics England, is to start investigating 13 February 2024
Bristol Myers Squibb has reported strong fourth quarter revenues of $11.5 billion and earnings per share (EPS) of $1.70, both higher than many analysts had fore 2 February 2024
Positive high-level results from the Japan Phase III trial of acoramidis in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) showed consistency to those 2 February 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.